Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 76 AL 90

Neuroinflammation in Alzheimer's Disease: The Preventive and Therapeutic Potential of Polyphenolic Nutraceuticals

Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A.

Adv Protein Chem Struct Biol. 2017;108:33-57. doi: 10.1016/bs.apcsb.2017.02.001. Epub 2017 Mar 22.

Iatrogenic systemic transthyretin amyloid deposits in a case with domino liver transplantation: an autopsy case study

Tsuda Y, Misumi Y, Ueda M, Tasaki M, Huang G, Masuda T, Suenaga G, Kinoshita Y, Obayashi K, Yamashita T, Ando Y.

Amyloid. 2017 Mar;24(sup1):125. doi: 10.1080/13506129.2017.1287071.

Ethical Considerations for Deep Brain Stimulation Trials in Patients with Early-Onset Alzheimer's Disease

Viaña JNM, Bittlinger M, Gilbert F.

J Alzheimers Dis. 2017;58(2):289-301. doi: 10.3233/JAD-161073.

Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications

Narayanan KB, Han SS.

Curr Protein Pept Sci. 2017 Aug 30;18(11):1141-1151. doi: 10.2174/1389203718666170424153109.

Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer's Disease

Shevtsova EF, Vinogradova DV, Neganova ME, Avila-Rodriguez M, Ashraf GM, Barreto GE, Bachurin SO, Aliev G.

CNS Neurol Disord Drug Targets. 2017;16(6):677-685. doi: 10.2174/1871527316666170424114444.

Impact of Nutritional Supplementation and a Psychomotor Program on Patients With Alzheimer's Disease

Vicente de Sousa O, Soares Guerra R, Sousa AS, Pais Henriques B, Pereira Monteiro A, Amaral TF.

Am J Alzheimers Dis Other Demen. 2017 Sep;32(6):329-341. doi: 10.1177/1533317517705221. Epub 2017 Apr 26.

Nanoparticles as potential clinical therapeutic agents in Alzheimer's disease: focus on selenium nanoparticles

Nazıroğlu M, Muhamad S, Pecze L.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):773-782. doi: 10.1080/17512433.2017.1324781. Epub 2017 May 16.

The Exceptional Vulnerability of Humans to Alzheimer's Disease

Walker LC, Jucker M.

Trends Mol Med. 2017 Jun;23(6):534-545. doi: 10.1016/j.molmed.2017.04.001. Epub 2017 May 5.

Emerging amyloid and tau targeting treatments for Alzheimer's disease

Khan A, Corbett A, Ballard C.

Expert Rev Neurother. 2017 Jul;17(7):697-711. doi: 10.1080/14737175.2017.1326819. Epub 2017 May 19.

Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets

Khan A, Corbett A, Ballard C.

Expert Rev Neurother. 2017 Jul;17(7):683-695. doi: 10.1080/14737175.2017.1326818. Epub 2017 May 18.

Alzheimer's disease, dementia, and stem cell therapy

Duncan T, Valenzuela M.

Stem Cell Res Ther. 2017 May 12;8(1):111. doi: 10.1186/s13287-017-0567-5.

Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer's disease

Knez D, Sova M, Košak U, Gobec S.

Future Med Chem. 2017 May;9(8):811-832. doi: 10.4155/fmc-2017-0036. Epub 2017 May 15.

Modulating 5-HT(4) and 5-HT(6) receptors in Alzheimer's disease treatment

Lalut J, Karila D, Dallemagne P, Rochais C.

Future Med Chem. 2017 May;9(8):781-795. doi: 10.4155/fmc-2017-0031. Epub 2017 May 15.

Multi-omics and Alzheimer's disease: a slower but surer path to an efficacious therapy?

Pimplikar SW.

Am J Physiol Cell Physiol. 2017 Jul 1;313(1):C1-C2. doi: 10.1152/ajpcell.00109.2017. Epub 2017 May 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias